🔗 Share this article

Chancellor Reeves has revealed she is planning "targeted measures to deal with cost of living challenges" in the upcoming financial statement.

During an interview with media outlets, she stated that curbing price rises is a collective duty of both the government and the central bank.

The United Kingdom's price growth is expected to be the highest among the G7 industrialized countries this year and next.

Potential Utility Cost Interventions

Reports indicate the administration could take action to bring down utility costs, for example by slashing the present 5% level of VAT applied on energy supplies.

A further approach is to lower some of the regulatory levies presently added to bills.

Fiscal Limitations and Expert Predictions

The government will receive the latest assessment from the independent fiscal watchdog, the Office for Budget Responsibility, on Monday, which will reveal how much scope there is for such actions.

The view from most economists is that Reeves will have to declare higher taxes or spending cuts in order to fulfill her self-imposed borrowing rules.

Previously on the same day, calculations suggested there was a twenty-two billion pound gap for the Treasury chief to resolve, which is at the lower end of expectations.

"There's a joint task between the Bank of England and the administration to continue tackling some of the causes of price increases," the Chancellor stated to reporters in the US capital, at the yearly gatherings of the International Monetary Fund and World Bank.

Tax Pledges and International Concerns

While much of the attention has been on probable tax increases, the chancellor said the latest figures from the fiscal watchdog had not altered her vow to election pledges not to raise rates on income tax, sales tax or National Insurance.

She attributed an "unpredictable global environment" with growing geopolitical and commercial issues for the fiscal tax moves, probably to be directed on those "most able to pay."

Global Trade Tensions

Addressing apprehensions about the UK's commercial links with the Asian nation she said: "The UK's security interests invariably come first."

Recent declaration by China to strengthen export controls on rare earths and other resources that are essential for advanced tech production led American leader Donald Trump to threaten an further 100% tariff on goods from China, raising the risk of an full-scale commercial conflict between the two economic giants.

The US Treasury Secretary described the Chinese decision "commercial pressure" and "a global supply chain control attempt."

Questioned on considering the US offer to join its conflict with the Asian nation, the Chancellor said she was "deeply worried" by China's measures and encouraged the Chinese government "to avoid restrictions and limit trade."

She said the action was "bad for the international commerce and causes additional headwinds."

"It is my opinion there are sectors where we should address China, but there are also significant chances to trade with China's economy, including financial services and other areas of the economy. We've got to achieve that balance appropriate."

The chancellor also stated she was working with G7 counterparts "regarding our own essential resources approach, so that we are reduced dependence."

Health Service Drug Pricing and Funding

The Chancellor also admitted that the price the National Health Service spends on drugs could increase as a consequence of current negotiations with the US government and its pharmaceutical firms, in return for lower tariffs and investment.

A number of the world's largest drug companies have said in recent statements that they are either delaying or scrapping investments in the United Kingdom, with several attributing the modest returns they are getting.

Last month, the government science advisor said the cost the health service spends on drugs would need to increase to stop firms and drug research funding leaving the UK.

The Chancellor informed media: "We have seen because of the pricing regime, that medical research, recent pharmaceuticals have not been available in the United Kingdom in the way that they are in other EU nations."

"The objective is to ensure that patients getting care from the NHS are can receive the top critical treatments in the globe. And so we are examining this situation, and... seeking to attract more investment into Britain."